About: RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy-on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in-69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/-kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was-found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a-much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year-event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant-difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.1 Aims and Methods: The goal was to investigate the effect of prior combined rituximab (R) and intensive chemotherapy-on peripheral blood stem cell mobilization and their engraftment after stem cell transplantation (ASCT) in-69 patients with poor-risk, diffuse large B-cell lymphoma (DLBCL). Results: A statistically comparable median number of CD34+ stem cells was collected in both groups (13.80x106/-kg in the non-R group and 7.81x106/kg in the R group; p = 0.110). A trend toward greater number of CFU-GM was-found in the non-R group (98.1x104/kg) compared to the R group (76.6x104/kg; p = 0.068). The non-R patients had a-much higher median number of BFU-E (90.9x104/kg) than the R patients (31.3x104/kg; p = 0.001). Conclusions: Hematopoietic engraftment was rapid for both groups and no different between them. The 3-year-event-free survival was 90.4 % in the R group and 67.2 % in the non-R group (p = 0.04), but there was no significant-difference in the 3-year overall survival (94,7 % vs 83,5 %; p = 0.1 (en)
Title	RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION (en)
skos:prefLabel	RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION (en)
skos:notation	RIV/61989592:15110/09:00009601!RIV10-MSM-15110___
http://linked.open...avai/riv/aktivita	Z
http://linked.open...avai/riv/aktivity	Z(MSM6198959205), Z(MSM6198959223)
http://linked.open...iv/cisloPeriodika	3
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Vondráková, Jana Skoumalová, Ivana PAPAJÍK, Tomáš Kubová, Zuzana Faber, Edgar INDRÁK, Karel Procházka, Vít Kučerová, Ladislava Pikalová, Zuzana
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	339438
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/09:00009601
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Diffuse large B-cell lymphoma; Rituximab; Stem cell transplantation (en)
http://linked.open.../riv/klicoveSlovo	Rituximab Diffuse large B-cell lymphoma Stem cell transplantation
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[A33F6B263466]
http://linked.open...i/riv/nazevZdroje	Biomedical Papers
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	9 (xsd:int)
http://linked.open...cetTvurcuVysledku	11 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	153
http://linked.open...iv/tvurceVysledku	Dušek, L. Faber, Edgar Indrák, Karel Kubová, Zuzana Pikalová, Zuzana Skoumalová, Ivana Vondráková, Jana Procházka, Vít Pavlík, T. Kučerová, Ladislava Papajík, Tomáš
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment Nové možnosti diagnostiky a imunomodulace u infekčních onemocnění a imunopatologických stavů
issn	1213-8118
number of pages	4 (xsd:int)
http://localhost/t...ganizacniJednotka	15110
is http://linked.open...avai/riv/vysledek of	RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION RITUXIMAB DOES NOT ADVERSELY AFFECT THE STEM CELL MOBILIZATION AND ENGRAFTMENT AFTER HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA IN FIRST COMPLETE OR PARTIAL REMISSION

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 112 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software